Activist All-Stars vs Biotech All-Star Tracker
A comparison of two published records. This is a side-by-side table of the same fields for each Portfolio. It is not a ranking, a score, or a recommendation.
Open in the interactive pickerPublished directory
| Field | Activist All-Stars Current as of 2026-10-05 HTMLMarkdownJSON | Biotech All-Star Tracker Current as of 2026-10-02 HTMLMarkdownJSON |
|---|---|---|
| Cite | HTMLMarkdownJSON | HTMLMarkdownJSON |
| Published Pilot | Jordan Grayson | Jordan Grayson |
| Sleeves | — | — |
| Slug | activist-all-stars | biotech-all-star-tracker |
| Portfolio key | 1240543 | 1259085 |
| Status | ACTIVE | ACTIVE |
| Provenance | Insufficient history | Insufficient history |
| Inception | 2026-07-08 | 2026-08-20 |
| As of | 2026-10-05 | 2026-10-02 |
| Window | 2026-07-08 → 2026-10-05 | 2026-08-20 → 2026-10-02 |
| Days live | 89 | 43 |
| Maturity | NASCENT | NASCENT |
| Risk band | LOW | MEDIUM |
| Objective | Activist investors use their ownership stake in a company to make changes in how a company is run or to advocate for a sale at a significant premium. After evaluating all current activist situations and doing a deep dive into their thesis, methodology and track record, we construct a portfolio of activist targets we believe have the highest likelihood of success with outsize returns and limited downside if we are wrong. | Baker Brothers and Perceptive Advisors are in my opinion the two best biotech hedge funds out there. They are investing legends in the biotech space. I look at their filings for ideas in the sector. This portfolio is based on the 13F filings for the two funds, which provides their US-based holdings as of the end of each quarter. I am taking the top 10 positions from each fund and forming a portfolio of 20 names, which will be rebalanced following each new 13F filing. |
| Past week net | n/a | n/a |
| Past week gross | n/a | n/a |
| 1Y net | n/a | n/a |
| 1Y gross | n/a | n/a |
| Since inception net | n/a | n/a |
| Since inception gross | n/a | n/a |
| All-time gross | n/a | n/a |
| CAGR net | n/a | n/a |
| CAGR gross | n/a | n/a |
| Sharpe | n/a | n/a |
| Sortino | n/a | n/a |
| Max DD | n/a | n/a |
| AUM | $2.2k | $132.9k |
| Current subscription | jordan grayson's Team - Full Access: Quarterly $49.99; Yearly $149.99 | jordan grayson's Team - Full Access: Quarterly $49.99; Yearly $149.99 |
About AutopilotBrowse thematic sleeves
Performance disclaimer
The performance data presented reflects the aggregated results of actual client portfolios managed by the Registered Investment Adviser (RIA), based on the trading activity in the securities contained in the relevant portfolio over the specified period. If fewer than 10 clients are invested in the portfolio, the data represents the aggregate performance of all clients following this strategy. Actual investor outcomes can vary due to factors like brokerage support for fractional shares, account size, trade timing, fees, and taxes, and past performance should not be interpreted as a guarantee of future results or typical of all portfolios. Performance figures are shown before Pilot subscription amounts. Autopilot does not charge an advisory fee.
"Autopilot" refers to Autopilot Holdings Corp and Autopilot Advisers, LLC, an SEC-registered investment adviser. Investing carries risk-including possible loss of principal-and past performance is not indicative of future results. Figures current as of 10/05/26. Performance shown reflects the period from 9/28/26 - 10/05/26. Standard-set returns for this Portfolio are not available on the published record. Not a recommendation. View important info at joinautopilot.com/disclaimer.
For agents
Canonical HTML: /compare/activist-all-stars-vs-biotech-all-star-tracker. Structured rows: /api/portfolios/compare?ids=activist-all-stars,biotech-all-star-tracker. This is an all-or-nothing pair, not a ranking.
Notes
This is a side-by-side table of the same fields for each Portfolio. It is not a ranking, a score, or a recommendation.
Autopilot does not charge an advisory fee and does not charge an AUM fee. The price to follow a Pilot is that Pilot's subscription. If you subscribe to more than one Pilot, those subscription amounts add. Pilot subscriptions are not deducted from the published return figures.
While individual Portfolios may each be suitable for your risk profile, combining multiple Portfolios may create concentration risks or unsuitable aggregate exposure. Autopilot does not assess aggregate suitability across multiple Portfolios.